Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Partnerships 21
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Licensing Agreements 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 25
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Expands its Licensing Agreement with ReGenX Biosciences 28
Equity Offering 30
Audentes Therapeutics Files Registration Statement to Raise up to USD86.3 Million in Public Offering of Shares 30
Audentes Therapeutics Raises USD75 Million in IPO 31
Acquisition 32
Audentes Therapeutics Acquires Cardiogen Sciences 32
Audentes Therapeutics Inc – Key Competitors 33
Audentes Therapeutics Inc – Key Employees 34
Audentes Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 14, 2017: Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 10, 2017: Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 38
May 11, 2017: Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 40
Mar 09, 2017: Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 42
Jan 09, 2017: Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance 45
Nov 10, 2016: Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update 48
Aug 31, 2016: Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update 49
Corporate Communications 51
Jun 13, 2017: Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors 51
May 08, 2017: Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer 52
Dec 13, 2016: Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors 53
Jan 05, 2016: Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors 54
Other Significant Developments 55
Nov 29, 2016: Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Audentes Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 25
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Expands its Licensing Agreement with ReGenX Biosciences 28
Audentes Therapeutics Files Registration Statement to Raise up to USD86.3 Million in Public Offering of Shares 30
Audentes Therapeutics Raises USD75 Million in IPO 31
Audentes Therapeutics Acquires Cardiogen Sciences 32
Audentes Therapeutics Inc, Key Competitors 33
Audentes Therapeutics Inc, Key Employees 34
Audentes Therapeutics Inc, Subsidiaries 35